Flufenamic acid-13C6

Flufenamic acid-13C6 is the 13C6 labeled Flufenamic acid. Flufenamic acid is a non-steroidal anti-inflammatory agent, inhibits cyclooxygenase (COX), activates AMPK, and also modulates ion channels, blocking chloride channels and L-type Ca2+ channels, modulating non-selective cation channels (NSC), activating K+ channels. Flufenamic acid binds to the central pocket of TEAD2 YBD and inhibits both TEAD function and TEAD-YAP-dependent processes, such as cell migration and proliferation.

Product Specifications

CAS Number

[1325559-30-5]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

AMPK; Calcium Channel; Chloride Channel; COX; Isotope-Labeled Compounds; Parasite; Potassium Channel

Type

Isotope-Labeled Compounds

Related Pathways

Anti-infection; Epigenetics; Immunology/Inflammation; Membrane Transporter/Ion Channel; Neuronal Signaling; Others; PI3K/Akt/mTOR

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/flufenamic-acid-13c6.html

Purity

99.5

Solubility

10 mM in DMSO

Smiles

OC([13C]([13CH]=[13CH][13CH]=[13CH]1)=[13C]1NC2=CC(C(F)(F)F)=CC=C2)=O

Molecular Formula

C8 13C6H10F3NO2

Molecular Weight

287.19

Precautions

H302, H315, H319, H335

References & Citations

[1]Guinamard R, et al. Flufenamic acid as an ion channel modulator. Pharmacol Ther. 2013 May;138 (2) :272-84.|[2]Pobbati AV, et al. Targeting the Central Pocket in Human Transcription Factor TEAD as a Potential Cancer Therapeutic Strategy. Structure. 2015;23 (11) :2076-2086.|[3]Pongkorpsakol P, et al. Cellular mechanisms underlying the inhibitory effect of flufenamic acid on chloride secretion in human intestinal epithelial cells. J Pharmacol Sci. 2017 Jun;134 (2) :93-100.|[4]Pongkorpsakol P, et al. Flufenamic acid protects against intestinal fluid secretion and barrier leakage in a mouse model of Vibrio cholerae infection through NF-κB inhibition and AMPK activation. Eur J Pharmacol. 2017 Mar 5;798:94-104.|[5]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53 (2) :211-216.